Regatta Bio

Regulatory T cell therapies to manage immune tolerance

Category
Oncology, Autoimmune
Location
Boston, MA
Website
Visit website

About the company

Regatta Bio is developing next-generation Treg therapies to overcome limitations in current approaches, targeting diseases such as stem cell and solid organ transplantation and autoimmune disorders. Their pipeline includes ex vivo expanded Tregs with low dose IL-2 for chronic Graft-versus-Host Disease and engineered IL-2-independent OX40L-CAR Tregs for enhanced immunosuppressant resistance.